On the recordApril 17, 2012
We have heard from many stakeholders that the provisions that were put in place have limited FDA's ability.
Source
congress.govEditor's note · Context
Burgess discusses concerns about conflict-of-interest provisions affecting FDA expertise.
Share
More from Michael Burgess
Dec 17, 2024
I reserve the balance of my time. Mr. McGOVERN. Mr. Speaker, I yield 4 minutes to the gentlewoman from New Mexico (Ms. Leger Fernandez), a distinguished member of the Rules Committee.
Dec 17, 2024
By direction of the Committee on Rules, I call up House Resolution 1616 and ask for its immediate consideration. The Clerk read the resolution, as follows: H. Res. 1616 Resolved, That upon adoption of this resolution it shall be in order…
Dec 4, 2024
Last night, the House Committee on Rules met to report House Resolution 1602, providing for consideration of two pieces of legislation. First, the rule provides for consideration of H.R. 5349, the Crucial Communism Teaching Act, under a…
Nov 13, 2024
Last week, the American people spoke forcefully against what we have seen for 4 years out of the Biden-Harris administration and their whole-of- government assault over individual freedom, economic prosperity, and limited government. For 4…
Other voices in this conversation
